Evaluation of Effects of Diabetes Mellitus, Hypercholesterolemia and Hypertension on Bell's Palsy.
facial nerve
facial palsy
prognosis
recovery rate
risk factors
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
10
04
2021
revised:
21
05
2021
accepted:
25
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The aim of this study is to evaluate the effects of diabetes mellitus, hypertension and hypercholesterolemia on the clinical presentation and outcome of Bell's palsy. The study (comorbidity) group consisted of 50 patients with Bell's palsy associated with diabetes, hypertension, or hypercholesterolemia; the control group included 46 patients with Bell's palsy, but without comorbid diseases. The House-Brackmann grading system (I to VI) was used in order to assess the initial and final facial functions. Both groups of patients were treated with steroids and the antiviral agent acyclovir. The mean severity of initial facial paralysis was more significant in diabetes, hypercholesterolemia, and hypertension, in comparison to the control group. Patients suffering from Bell's palsy and concomitant comorbidities have a poorer prognosis (HB III-VI) compared to patients without comorbidities. Increased glycosylated hemoglobin A1c levels (>6.7%) were significantly correlated with unsatisfactory facial recovery. The pathogenetic mechanisms by which diabetes, hypercholesterolemia, and hypertension affect the vasa nervosum of facial nerve have been described.
Identifiants
pubmed: 34072018
pii: jcm10112357
doi: 10.3390/jcm10112357
pmc: PMC8198958
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Arch Otorhinolaryngol. 1998;255(3):166-7
pubmed: 9561867
Eur Arch Otorhinolaryngol. 2014 Jul;271(7):1891-5
pubmed: 23995770
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):341-3
pubmed: 21551169
NCHS Data Brief. 2017 Oct;(290):1-8
pubmed: 29155686
J Neurol Neurosurg Psychiatry. 1982 Jul;45(7):652-5
pubmed: 7119834
Acta Otolaryngol. 2018 Jul;138(7):670-674
pubmed: 29374993
J Am Board Fam Med. 2012 Nov-Dec;25(6):819-26
pubmed: 23136321
Otol Neurotol. 2009 Apr;30(3):402-7
pubmed: 19318892
Am J Phys Med. 1973 Aug;52(4):195-7
pubmed: 4352896
Acta Neurol Scand. 2011 Jan;123(1):68-72
pubmed: 20545630
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Acta Otolaryngol. 2007 Aug;127(8):888-91
pubmed: 17763003
Ann Otol Rhinol Laryngol Suppl. 1988 Nov-Dec;137:5-7
pubmed: 3144232
Neurosci Lett. 2007 May 18;418(3):222-6
pubmed: 17400385
Acta Otolaryngol Suppl. 2002;(549):4-30
pubmed: 12482166
Acta Otolaryngol Suppl. 1988;446:93-6
pubmed: 3166596
Otol Neurotol. 2011 Aug;32(6):1031-6
pubmed: 21725266
Arch Intern Med. 2004 Nov 22;164(21):2383-5
pubmed: 15557420
Eur Arch Otorhinolaryngol. 2019 Apr;276(4):1011-1016
pubmed: 30707280
Am J Hypertens. 2013 Mar;26(3):351-6
pubmed: 23382485
Autoimmun Rev. 2012 Dec;12(2):323-8
pubmed: 22684016
BMJ. 2018 Sep 4;362:k1497
pubmed: 30181166
Medicine (Baltimore). 2015 Jun;94(22):e952
pubmed: 26039136
Auris Nasus Larynx. 2007 Jun;34(2):159-64
pubmed: 17055202
Eur Neurol. 2008;60(5):253-7
pubmed: 18756090
JAMA Otolaryngol Head Neck Surg. 2020 Mar 1;146(3):256-263
pubmed: 31971554
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Can J Diabetes. 2018 Aug;42(4):433-436
pubmed: 29284561